FY2024 Earnings Estimate for Affimed Issued By HC Wainwright

Affimed (NASDAQ:AFMD) – Equities researchers at HC Wainwright boosted their FY2024 EPS estimates for shares of Affimed in a report issued on Wednesday, December 18th. HC Wainwright analyst S. Ramakanth now expects that the biopharmaceutical company will earn ($4.28) per share for the year, up from their prior estimate of ($4.31). HC Wainwright has a “Buy” rating and a $10.00 price objective on the stock. The consensus estimate for Affimed’s current full-year earnings is ($4.00) per share. HC Wainwright also issued estimates for Affimed’s Q4 2024 earnings at ($0.93) EPS, Q3 2025 earnings at ($0.91) EPS, Q4 2025 earnings at ($0.67) EPS and FY2025 earnings at ($3.02) EPS.

AFMD has been the topic of several other reports. Stifel Nicolaus dropped their price objective on shares of Affimed from $5.00 to $4.00 and set a “hold” rating on the stock in a report on Friday, November 15th. Cantor Fitzgerald restated an “overweight” rating on shares of Affimed in a research report on Tuesday, November 19th. Finally, Wells Fargo & Company lowered their price target on Affimed from $20.00 to $15.00 and set an “overweight” rating on the stock in a research note on Thursday, December 12th. One equities research analyst has rated the stock with a sell rating, one has given a hold rating and four have issued a buy rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $13.50.

Affimed Stock Performance

Affimed stock opened at $1.24 on Monday. The business’s 50-day simple moving average is $2.84 and its two-hundred day simple moving average is $3.95. Affimed has a fifty-two week low of $1.14 and a fifty-two week high of $8.95. The company has a current ratio of 1.93, a quick ratio of 1.93 and a debt-to-equity ratio of 0.13.

Institutional Investors Weigh In On Affimed

Several hedge funds and other institutional investors have recently bought and sold shares of AFMD. Point72 Asset Management L.P. grew its stake in shares of Affimed by 4.6% in the 3rd quarter. Point72 Asset Management L.P. now owns 342,856 shares of the biopharmaceutical company’s stock valued at $1,152,000 after buying an additional 15,108 shares during the period. Jane Street Group LLC acquired a new position in Affimed in the third quarter valued at approximately $44,000. Intellectus Partners LLC lifted its holdings in Affimed by 12.2% in the third quarter. Intellectus Partners LLC now owns 94,361 shares of the biopharmaceutical company’s stock valued at $317,000 after acquiring an additional 10,250 shares during the last quarter. Choreo LLC purchased a new position in Affimed in the second quarter worth approximately $54,000. Finally, FMR LLC increased its stake in Affimed by 30.0% during the third quarter. FMR LLC now owns 17,696 shares of the biopharmaceutical company’s stock worth $59,000 after acquiring an additional 4,086 shares during the last quarter. 30.82% of the stock is currently owned by institutional investors and hedge funds.

About Affimed

Affimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in the United States and Germany. The company’s lead product candidates include AFM13 that has completed Phase 2 clinical trial for CD30-positive lymphoma, Phase Ib clinical trial for hodgkin lymphoma, and completed Phase IIb clinical study for peripheral T-cell lymphoma; AFM24, a tetravalent, bispecific epidermal growth factor receptor, and CD16A-binding innate cell engager, which is in Phase IIa clinical trial for the treatment of advanced cancers; and AFM28, an innate cell engager (ICE), which is in preclinical development for the treatment acute myeloid.